A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...

The prevalence of type 2 diabetes is increasing because the population is aging and becoming more obese and more sedentary. Diabetes has become the most common cause of new blindness, end-stage renal ...

What if there were a straightforward and relatively inexpensive way to lower the incidence of heart failure (HF), renal disease, stroke, and cognitive impairment? Cardiologist Bertram Pitt, MD, said ...

A steroid hormone called aldosterone is linked to an increased risk of kidney failure in patients with chronic kidney disease (CKD), according to a study published in the European Heart Journal [1] ...

Unprecedented access to a unique group of Australians is allowing researchers to study links between raised aldosterone levels and elevated cardiovascular risk in various age groups—with important ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and ...

Nine normal volunteer subjects (6 males and 3 females), nineteen to thirty-six years of age, and 5 patients with primary aldosteronism (3 females and 2 males), forty to fifty-two years of age, were ...

Hypertension affects 1 in 3 adults globally and is the leading modifiable risk factor for cardiovascular disease. Aldosterone dysregulation, often driven by obesity and primary aldosteronism, affects ...

Please provide your email address to receive an email when new articles are posted on . Aldosterone is associated with an increased risk of chronic kidney disease progression and the development of ...